Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
29. November 2018 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
27. November 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
19. November 2018 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
09. November 2018 08:00 ET
|
Scholar Rock
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors Vulnerable to PD1...
Scholar Rock to Present at the Jefferies 2018 London Healthcare Conference
31. Oktober 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock to Present Preclinical Data Highlighting the Role of TGFβ1 Inhibition in Overcoming Checkpoint Resistance at the SITC Annual Meeting
01. Oktober 2018 17:06 ET
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Reports Second Quarter 2018 Financial Results and Updates on Business Progress
08. August 2018 16:08 ET
|
Scholar Rock
Completed Initial Public Offering Raising $86.3 Million in Gross ProceedsInitiated Enrollment in Multiple-Ascending Dose Portion of Phase 1 Clinical Trial for SRK-015On Track to Initiate Phase 2...
Scholar Rock to Participate in Upcoming Investor Conferences
02. August 2018 09:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
04. Juni 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...
Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
31. Mai 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...